Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the quality, safety, and efficacy of therapeutic goods available in Australia. One of the key provisions of this Act is the licensing of manufacturers of therapeutic goods, ensuring that only products that meet stringent standards are made available to the public. This legislative measure was designed to address the need for a comprehensive regulatory framework that protects public health by controlling the manufacturing of therapeutic goods. The publication of the list of manufacturers granted a licence under Section 38 of the Act serves to inform the public and other stakeholders about entities authorised to produce these goods, thereby reinforcing the regulatory oversight and accountability within the therapeutic goods industry.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, or importation of therapeutic goods within Australia, including individuals and corporations. The scope of the Act encompasses a wide range of products such as medicines, medical devices, blood, and tissues, ensuring they meet safety, quality, and efficacy standards. The Act operates on a national level across the Commonwealth of Australia, applying uniformly to all states and territories. The Act grants the Therapeutic Goods Administration (TGA) the authority to issue licences for the manufacture of therapeutic goods, as evidenced by the licence granted to Peter MacCallum Cancer Institute and Labceuticals Pty Ltd, reflecting its broad jurisdictional reach. Additionally, the Act may extend its application through subordinate instruments, allowing for the detailed regulation of specific therapeutic goods and their associated manufacturing processes. This legislative framework ensures that therapeutic goods available in Australia are held to the highest standards of safety and quality.

Key Provisions

The Therapeutic Goods Act 1989, through Section 38, provides the framework for granting licences to entities for the manufacture of therapeutic goods. This legislative action allows the Secretary of the Department of Health, Therapeutic Goods Administration, to issue written notices granting such licences (s.38). In this instance, the Therapeutic Goods Administration has issued a notice granting a licence to Peter MacCallum Cancer Institute, with Licence Number MI-2015-LI-10773-1, and Labceuticals Pty Ltd, with Licence Number MI-2016-LI-11619-1. These licences are specific to their respective locations, with Peter MacCallum Cancer Institute based at Level 4 Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, and Labceuticals Pty Ltd located at 9-11 Antill Street, Yennora, NSW, 2161. The licences impose several obligations on the recipients, including compliance with all relevant legislative and regulatory requirements pertaining to the manufacture of therapeutic goods. This encompasses adhering to Good Manufacturing Practice (GMP) standards, ensuring that all therapeutic goods are manufactured in a manner that maintains their quality and safety, and maintaining appropriate records of all manufacturing activities. Both entities must also ensure that their facilities and processes are regularly inspected and assessed by the Therapeutic Goods Administration to verify compliance with these standards. Any changes to their manufacturing processes or facilities must be reported to the Administration before implementation. Failure to comply with the obligations of the licence or the Therapeutic Goods Act 1989 can result in severe consequences. The Act provides for both civil and criminal penalties for breaches. Civil penalties may include fines of up to $1,650 for individuals and up to $82,500 for corporations for each day of non-compliance. Criminal penalties can include fines of up to $1,100,000 for individuals and $5,500,000 for corporations, along with potential imprisonment for up to 5 years. Additionally, the Administration has the authority to suspend or revoke the licence, effectively shutting down the manufacturing operations of the entity in question. These stringent penalties underscore the importance of strict adherence to the legislative requirements governing the manufacture of therapeutic goods.